Brief: Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial
15/04/2024 13:35
April 15 (Reuters) - Atossa Therapeutics Inc ATOS.O :
* ATOSSA THERAPEUTICS AND QUANTUM LEAP HEALTHCARE ANNOUNCE
I-SPY 2
CLINICAL TRIAL TO EVALUATE (Z)-ENDOXIFEN IN COMBINATION WITH
ABEMACICLIB (VERZENIO®) IN WOMEN WITH ER+/HER2- BREAST CANCER
* ATOSSA THERAPEUTICS: UNDER TERMS OF STUDY, CO WILL CONDUCT
STUDY
WITH ATOSSA & ELI LILLY AND CO EACH RESPONSIBLE FOR SUPPLYING
RESPECTIVE STUDY DRUGS
Source text for Eikon: ID:nGNX5HlVdd
Further company coverage: ATOS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atossa Therapeutics
See all newsAtossa Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Atossa Therapeutics Q3 net loss narrows as clinical trial expenses decline
Brief: Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation In Potential Priority Review Voucher Value
US RESEARCH ROUNDUP-Amrize, Dexcom, Lennar
Atossa Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary